SEC Form 4 · accession 0000880771-17-000039
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hong Zhao
Officer — CEO, China Operations
Period of report
Mar 8, 2017
Accepted (ET)
Mar 9, 2017 · 5:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2,F3 | — | Mar 8, 2017 | A | 12,000 | A | — | Mar 8, 2027 | Common Stock | 12,000 | 125,500 | D |
| Non-Qualified Stock Option (right to buy)F1,F4 | $9.65 | Mar 8, 2017 | A | 84,000 | A | — | Mar 8, 2027 | Common Stock | 84,000 | 84,000 | D |
Explanation of responses
- F1Granted under the Issuer's 2015 Equity Incentive Plan.
- F2Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F3Vesting for such RSUs will occur 25% on March 8, 2018, 25% on March 8, 2019, 25% on March 8, 2020, and 25% on March 8, 2021, contingent upon the executive's continued employment.
- F425% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.